According to the Centers for Disease control and Prevention in 2015, 16.8 million people in the US visited hospitals due to infectious and parasitic diseases. In Africa, chronic viral hepatitis affects around 70 million Africans (60 million with Hepatitis B and 10 million with Hepatitis C).
The disease impacts the most important part of the African population i.e. youths and earning African population which are causing tremendous rise in financial debts incurred for the treatment of advanced liver diseases and emotional distress. In developed countries, the cases of infectious diseases has decreased in the past decade, but there has been a rise of re-emerging diseases worldwide, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), measles, avian and pandemic influenza, chikungunya virus, Ebola virus disease (EVD) and Zika virus disease, which has attracted a renewed focus on infectious diseases around the developed countries. Thus the growing global prevalence of infectious diseases are expected to encourage the leading market players for the development of new and effective drugs and vaccines.
The Asia Pacific vaccines market is expected to grow at highest rate during the forecast period owing to rapid growth of pharmaceutical industries, emergence of new local players with competitive vaccine portfolio.
Get Sample Report at https://www.theinsightpartners.com/sample/TIPRE00003424
Driving factors such as, growing focus on immunization programs, increasing support for vaccine development, rising prevalence of infectious diseases. However, the complexity and cost of vaccine manufacturing and soaring costs of vaccines are likely to pose a negative impact on the market growth. On the other hand, robust pipeline of vaccines is likely to have a positive impact on the growth of the global vaccines market in the coming years.
The epidemic of measles in Disneyland in California, US has enforced the dropping of the rates for the vaccination. The instance took place in 2014, the epidemic of the measles has sickened approximately 111 people in California and has also spread to six other states as well as Canada and Mexico. The vaccination has been used safely and effectively for the decades and the rising numbers of the measles has led to more vaccinations. The children are more susceptible to falling prey to the diseases, therefore majority of the parents in US vaccinate their children on schedule.
US is expected to lead the market in the North American region due to the rapid growth of the biopharmaceutical industry. The industry is experiencing the rapid growth due to technological advancements and increasing flexibility and low operational cost are also adding to the growth of the market. In addition, in the country the government has mandate the immunization and vaccination for preventable diseases. The growth of the market is also defined by the rising prevalence of the infectious and parasitic diseases as the diseases are alarming the need of the vaccination in the country. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North American region during the forecast period.
Vaccination saves lives and improves quality of life. For instance, Polio is an infectious disease caused by poliovirus and causes muscle weakness that results in an inability to move, which further hampers the quality of life. Polio vaccine protects an individual against polio. The vaccine produces antibodies in the bloodstream against the poliovirus. Due to the strong promotion of Polio vaccine in Europe, the World Health Organization in 2002, declared the European Region polio-free.
Check Discount at https://www.theinsightpartners.com/discount/TIPRE00003424
Rising prevalence of infectious diseases is expected to boost the market growth over the years
In the current era, there are increasing concerns of spread of infectious diseases with the changing environment. These emerging infectious diseases are a burden on public health but have also an impact on global economies. The new diseases such as HIV, hepatitis, dengue have attracted a huge concern for the government of the respective countries. There is also resurgence of diseases which seemed to be under control such as malaria, cholera and many more. According to the Centers for Disease control and Prevention in 2015, 16.8 million people in the US visited hospitals due to infectious and parasitic diseases. In Africa, chronic viral hepatitis affects around 70 million Africans (60 million with Hepatitis B and 10 million with Hepatitis C).
The disease impacts the most important part of the African population i.e. youths and earning African population which are causing tremendous rise in financial debts incurred for the treatment of advanced liver diseases and emotional distress. In developed countries, the cases of infectious diseases has decreased in the past decade, but there has been a rise of re-emerging diseases worldwide, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), measles, avian and pandemic influenza, chikungunya virus, Ebola virus disease (EVD) and Zika virus disease, which has attracted a renewed focus on infectious diseases around the developed countries. Thus the growing global prevalence of infectious diseases are expected to encourage the leading market players for the development of new and effective drugs and vaccines.
Increasing Support for Vaccine Development
In addition to the funds from traditional research-funding institutions, the Gates Foundation has invested hundreds of millions of dollars in R&D of new vaccines against the leading killers of children and adults everywhere. GAVI has established public-private partnerships to accelerate late-stage development and introduction of priority vaccines against diseases such as rotavirus and pneumococcus. These partnerships are designed to work with governments, donors, and industry to streamline demand, supply, and financing decisions. They coordinate and fund the efforts of partners supporting national decision makers whether to introduce these new products, ensuring a reliable and sustainable supply of affordable vaccine to developing countries, and reducing risks and creating incentives for private investment to ensure access to the product. Global Vaccine Fund commits $150 Million in vaccines and funding over five years to 13 developing countries. Countries will receive financial and technical assistance in order to strengthen basic immunization systems and to introduce newer, under-used vaccines such as hepatitis B and Haemophilus influenzae type b (Hib). Some countries will receive support in both areas. Thus the growing support for vaccine development is likely to favor market growth.
Strategic Insights
Product approvals and collaborations were observed as the most adopted strategy in global vaccines industry. Few of the recent product key developments are listed below:
2019: Merck, known as MSD outside of the United States and Canada, announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD). The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of drugs intended for serious or life-threatening conditions.
2018: The European Commission has granted marketing authorization for Dengvaxia, Sanofi’s dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas.
2018: Pfizer entered into a multi-year research and development (R&D) collaboration with BioNTech AG to develop mRNA-based vaccines
Buy this Report now at https://www.theinsightpartners.com/buy/TIPRE00003424
Media Contact
Company Name: The Insight Partners
Contact Person: Sam J
Email: Send Email
Phone: +1-646-491-9876
Address:Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com